Percutaneous coronary intervention for all patients with complex coronary disease: Three-vessel or left main coronary artery disease. True? False? Unknown?;Intervencionismo coronario percutáneo para todos los pacientes con enfermedad coronaria compleja: enfermedad de tres vasos o del tronco izquierdo. ¿verdadero? ¿falso? ¿no se sabe?

Revista Espanola de Cardiologia

Volumn 62, Issue 7, 2009, Pages 719-725

  Serruys, Patrick ^a   Garg, Scot ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE OUTCOME; CARDIAC PATIENT; CLINICAL PRACTICE; CORONARY ARTERY BYPASS SURGERY; DIABETIC PATIENT; EDITORIAL; EVIDENCE BASED MEDICINE; HUMAN; LEFT CORONARY ARTERY; PERCUTANEOUS CORONARY INTERVENTION; CORONARY ARTERY DISEASE; PATIENT SELECTION; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY DISEASE; HUMANS; PATIENT SELECTION;

EID: 67749109910     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/S0300-8932(09)71683-5     Document Type: Editorial

References (27)

1. W.E. Boden, R.A. O'Rourke, K.K. Teo, P.M. Hartigan, D.J. Maron, and W.J. Kostuk Optimal medical therapy with or without PCI for stable coronary disease N Engl J Med 356 2007 1503 1516
2. D. Taggart The DELFT (Drug Eluting stent for LeFT main) Registry: The Unknowns J Am Coll Cardiol 52 2008 1680 1681
3. E. Meliga, A.O. Maree, H.M. García-García, and P.W. Serruys Reply J Am Coll Cardiol 52 2008 1681
4. D.P. Taggart, S. Kaul, W.E. Boden, T.B. Ferguson Jr, R.A. Guyton, and M.J. Mack Revascularization for unprotected left main stem coronary artery stenosis stenting or surgery J Am Coll Cardiol 51 2008 885 892
5. N.H. Lopes, Fd.S. Paulitsch, A.F. Gois, A.C. Pereira, N.A. Stolf, and L.O. Dallan Impact of number of vessels disease on outcome of patients with stable coronary artery disease: 5-year follow-up of the Medical, Angioplasty, and bypass Surgery Study (MASS) Eur J Cardiothorac Surg 33 2008 349 354
6. P.W. Serruys, F. Unger, J.E. Sousa, A. Jatene, H.J. Bonnier, and J.P. Schonberger Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease N Engl J Med 344 2001 1117 1124 (Pubitemid 32285232)
7. I. Sim, M. Gupta, K. McDonald, M.G. Bourassa, and M.A. Hlatky A meta-analysis of randomized trials comparing coronary artery bypass grafting with percutaneous transluminal coronary angioplasty in multivessel coronary artery disease Am J Cardiol 76 1995 1025 1029
8. S.J. Pocock, R.A. Henderson, A.F. Rickards, J.R. Hampton, S.B. King 3rd, and C.W. Hamm Meta-analysis of randomised trials comparing coronary angioplasty with bypass surgery Lancet 346 1995 1184 1189
9. J. Daemen, E. Boersma, M. Flather, J. Booth, R. Stables, and A. Rodríguez Long-term safety and efficacy of percutaneous coronary intervention with stenting and coronary artery bypass surgery for multivessel coronary artery disease: a meta-analysis with 5-year patient-level data from the ARTS, ERACI-II, MASS-II, and SoS trials Circulation 118 2008 1146 1154
10. M.A. Hlatky, D.B. Boothroyd, D.M. Bravata, E. Boersma, J. Booth, and M.M. Brooks Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials Lancet 373 2009 1190 1197
11. P.W. Serruys, A.T.L. Ong, M.C. Morice, B. De Bruyne, A. Colombo, and C. Macaya Arterial Revascularisation Therapies Study Part II - Sirolimus-eluting stents for the treatment of patients with multivessel de novo coronary artery lesions EuroIntervention 1 2005 147 156
12. P.A. Lemos, P.W. Serruys, R.T. Van Domburg, F. Saia, C.A. Arampatzis, and A. Hoye Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry Circulation 109 2004 190 195
13. B.R. Brodie, T. Stuckey, W. Downey, A. Humphrey, B. Bradshaw, and C. Metzger Outcomes and complications with off-label use of drug-eluting stents: Results from the STENT (Strategic Transcatheter Evaluation of New Therapies) Group J Am Coll Cardiol Intv 1 2008 405 414
14. A.P. Kappetein, K.D. Dawkins, F.W. Mohr, M.C. Morice, M.J. Mack, and M.E. Russell Current percutaneous coronary intervention and coronary artery bypass grafting practices for three-vessel and left main coronary artery disease. Insights from the SYNTAX run-in phase Eur J Cardiothorac Surg 29 2006 486 491
15. S.C. Smith, T.E. Feldman, J.W. Hirshfeld, A.K. Jacobs, M.J. Kern, and S.B. King ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention) Circulation 113 2006 e166 e286
16. P.W. Serruys, M.C. Morice, A.P. Kappetein, A. Colombo, D.R. Holmes, and M.J. Mack Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease N Engl J Med 360 2009 961 972
17. G. Sianos, M.A. Morel, A.P. Kappetein, M.C. Morice, A. Colombo, and K. Dawkins The SYNTAX score: an angiographic tool grading the complexity of coronary artery disease EuroIntervention 1 2005 219 227
18. A. Banning Revascularisation with cardiac surgery versus paclitaxel eluting stents in patients with diabetes and metabolic syndrome. 1 year results from the SYNTAX study J Am Coll Cardiol 53 Suppl A 2009 A3
19. Garg S, Serruys PW. Secondary revascularisation, mediations following the SYNTAX trial. Eurointervention. 2009 [en prensa].
20. P.W. Serruys, M.C. Morice, A.P. Kappetein, A. Colombo, D.R. Holmes, and M.J. Mack Supplementary appendix - Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease N Engl J Med 360 2009 961 972
21. P. Vranckx, E. Meliga, P.P. De Jaegere, M. Van den Ent, E.S. Regar, and P.W. Serruys The TandemHeart, percutaneous transseptal left ventricular assist device: a safeguard in high-risk percutaneous coronary interventions. The six-year Rotterdam experience EuroIntervention 4 2008 331
22. Y.H. Kim, J.M. Ahn, D.W. Park, B.K. Lee, C.W. Lee, and M.K. Hong EuroSCORE as a predictor of death and myocardial infarction after unprotected left main coronary stenting Am J Cardiol 98 2006 1567 1570
23. P.E. Buszman, S.R. Kiesz, A. Bochenek, E. Peszek-Przybyla, I. Szkrobka, and M. Debinski Acute and late outcomes of unprotected left main stenting in comparison with surgical revascularization J Am Coll Cardiol 51 2008 538 545
24. E. Meliga, H.M. García-García, M. Valgimigli, A. Chieffo, G. Biondi-Zoccai, and A.O. Maree Longest available clinical outcomes after drug-eluting stent implantation for unprotected left main coronary artery disease: The DELFT (Drug Eluting stent for LeFT main) Registry J Am Coll Cardiol 51 2008 2212 2219
25. K.B. Seung, D.W. Park, Y.H. Kim, S.W. Lee, C.W. Lee, and M.K. Hong Stents versus coronary-artery bypass grafting for left main coronary artery disease N Engl J Med 358 2008 1781 1792
26. Mehilli J, Kastrati A, Byrne RA, Bruskina O, Iijima R, Schulz S, et al. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease. J Am Coll Cardiol. Epub 25 Feb 2009. doi:10.1016/j.jacc.2009.01. 035.
27. Federspiel J, Stearns S, Van Domburg R, Sheridan B, Lund J, Serruys P. Risk-benefit trade-offs in revascularization choices. Med Decis Making. 2009 [en prensa].